What drove the 48% revenue growth in the first quarter of 2026?

Most of the growth came from Screening, where revenue increased to $41.6 million from $5.7 million as Shield test volume rose to about 44,000 from 9,000 and reimbursement improved. Oncology contributed $54.4 million of the $98.2 million total increase, on 47% higher volume and better reimbursement. Biopharma & Data grew 17%, adding about $7.6 million.

Is Guardant Health closer to profitability?

On a non-GAAP basis, results improved modestly: the non-GAAP net loss narrowed to $58.7 million from $61.1 million. On a GAAP basis, the net loss widened to $112.1 million from $95.2 million, largely because of higher stock-based compensation and sales and marketing spending. Free cash flow was slightly more negative at $(71.2) million, so the company is still burning cash and does not yet report positive cash generation.

Did management change its 2026 outlook?

Yes, in a positive direction for revenue. Total 2026 revenue guidance rose to $1.30–$1.32 billion from $1.25–$1.28 billion, with Screening and oncology volume expectations raised. Non-GAAP operating expense guidance also increased, to $1.05–$1.07 billion from $1.03–$1.05 billion. The free cash flow burn outlook of $185–$195 million and the non-GAAP gross margin outlook of 64%–65% were maintained.

How strong is the company's balance sheet?

The company reported about $1.2 billion of cash, cash equivalents, restricted cash and marketable securities at March 31, 2026. Against that, it had $1.5 billion of convertible senior notes outstanding. Total stockholders' deficit grew to $181.1 million from $99.3 million, mainly because of accumulated losses. Much of the increase in cash on the balance sheet reflects marketable securities converted to cash, not new cash generation.

What are the main risks highlighted by this quarter's results?

Key risks include the cost of scaling Shield and oncology commercial operations, since sales and marketing expense rose 62% year over year and non-GAAP operating expense guidance was raised. Continued cash burn, with a full-year guided free cash flow burn of $185–$195 million, and the stockholders' deficit and convertible debt load are also points to monitor. The company's forward-looking statements caution that results could differ materially from expectations, citing risks described in its 2025 Form 10-K.

GH 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed May 7, 2026. Cited figures are marked; the original filing is the authoritative source.

Guardant Health reported first quarter 2026 revenue of $301.7 million^a, up 48% year over year from $203.5 million.

Growth came mainly from Screening, where Shield revenue rose to $41.6 million^b from $5.7 million on about 44,000 tests versus 9,000 a year earlier. Oncology revenue grew 36% to $205.0 million on 47% higher test volume (about 86,000 tests), and Biopharma & Data grew 17% to $53.0 million. GAAP gross margin was 65% and non-GAAP gross margin was 66%, both up from the prior year.

Profitability remains negative, though the non-GAAP picture is steadier. GAAP net loss widened to $112.1 million^c ($0.85 per share) from $95.2 million, driven by higher sales and marketing spending (up 62%) to build out Shield and oncology commercial infrastructure. Non-GAAP net loss narrowed to $58.7 million from $61.1 million, and adjusted EBITDA loss was roughly flat at $58.9 million.

Free cash flow was negative $71.2 million^d, compared with negative $67.1 million a year earlier. Cash, cash equivalents, restricted cash and marketable securities totaled about $1.2 billion at March 31, 2026, against $1.5 billion of convertible senior notes on the balance sheet. The stockholders' deficit widened to $181.1 million from $99.3 million.

Management raised 2026 revenue guidance to $1.30 to $1.32 billion (32% to 34% growth), up from $1.25 to $1.28 billion. Screening revenue guidance rose to $186 to $198 million on Shield volume of 230,000 to 245,000 tests, and oncology volume growth is now expected to exceed 35%.

The company also raised its non-GAAP operating expense outlook to $1.05 to $1.07 billion, while keeping its free cash flow burn guidance at $185 to $195 million and its non-GAAP gross margin guidance at 64% to 65%. Investors will want to track whether Shield volume and reimbursement can keep scaling while operating expenses rise.

02—Key points

Key Highlights

Total Q1 2026 revenue rose 48% to $301.7 million, led by Screening (Shield) revenue of $41.6 million versus $5.7 million a year earlier.
Oncology revenue grew 36% to $205.0 million on 47% higher test volume of about 86,000 tests; Biopharma & Data grew 17% to $53.0 million.
Non-GAAP net loss narrowed to $58.7 million ($0.45 per share) from $61.1 million, while GAAP net loss widened to $112.1 million from $95.2 million.
Adjusted EBITDA loss was $58.9 million, roughly flat versus $58.5 million, and free cash flow was negative $71.2 million versus negative $67.1 million.
2026 revenue guidance raised to $1.30–$1.32 billion (from $1.25–$1.28 billion), with Screening guidance raised to $186–$198 million on 230,000–245,000 Shield tests.
Non-GAAP operating expense guidance increased to $1.05–$1.07 billion from $1.03–$1.05 billion, reflecting continued commercial investment.
Liquidity of about $1.2 billion at March 31, 2026 (including restricted cash) compares with $1.5 billion of convertible senior notes; the stockholders' deficit widened to $181.1 million.

03—Questions

Frequently Asked Questions

What drove the 48% revenue growth in the first quarter of 2026?
Most of the growth came from Screening, where revenue increased to $41.6 million from $5.7 million as Shield test volume rose to about 44,000 from 9,000 and reimbursement improved. Oncology contributed $54.4 million of the $98.2 million total increase, on 47% higher volume and better reimbursement. Biopharma & Data grew 17%, adding about $7.6 million.
Is Guardant Health closer to profitability?
On a non-GAAP basis, results improved modestly: the non-GAAP net loss narrowed to $58.7 million from $61.1 million. On a GAAP basis, the net loss widened to $112.1 million from $95.2 million, largely because of higher stock-based compensation and sales and marketing spending. Free cash flow was slightly more negative at $(71.2) million, so the company is still burning cash and does not yet report positive cash generation.
Did management change its 2026 outlook?
Yes, in a positive direction for revenue. Total 2026 revenue guidance rose to $1.30–$1.32 billion from $1.25–$1.28 billion, with Screening and oncology volume expectations raised. Non-GAAP operating expense guidance also increased, to $1.05–$1.07 billion from $1.03–$1.05 billion. The free cash flow burn outlook of $185–$195 million and the non-GAAP gross margin outlook of 64%–65% were maintained.
How strong is the company's balance sheet?
The company reported about $1.2 billion of cash, cash equivalents, restricted cash and marketable securities at March 31, 2026. Against that, it had $1.5 billion of convertible senior notes outstanding. Total stockholders' deficit grew to $181.1 million from $99.3 million, mainly because of accumulated losses. Much of the increase in cash on the balance sheet reflects marketable securities converted to cash, not new cash generation.
What are the main risks highlighted by this quarter's results?
Key risks include the cost of scaling Shield and oncology commercial operations, since sales and marketing expense rose 62% year over year and non-GAAP operating expense guidance was raised. Continued cash burn, with a full-year guided free cash flow burn of $185–$195 million, and the stockholders' deficit and convertible debt load are also points to monitor. The company's forward-looking statements caution that results could differ materially from expectations, citing risks described in its 2025 Form 10-K.

04—Continue

← View all 8-K filings